This episode focuses on Steatotic Liver Disease (SLD). In 2023, EASL officially launched a global coalition, the Healthy Livers Healthy Lives, which brings together the four main professional liver societies, and aims to raise awareness on SLD. Discover what the coalition has achieved so far and its ultimate goal. The key issue of diagnostics for SLD and stratification pathways is being thoroughly discussed. What is the landscape of diagnostics for SLD? How non-invasive tests are being used in practice and what’s the situation around stratification pathways?

The EASL Policy Dialogues are supported by CymaBay, Echosens, Grifols and Novo Nordisk. CymaBay, Echosens, Grifols and Novo Nordisk have had no input into the content of the EASL Policy Dialogues.



Jeffrey Lazarus

Jeffrey V. Lazarus (Ph.D., MIH, MA) is a Member of the EASL Policy and Public Health Committee. He holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18). Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission. At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Maja Thiele

Prof. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, AASLD clinical guidance, WFUMB guideline, and The Lancet Commission on liver disease in primary care. Partner in the European research consortia GALAXY, LiverScreen, LIVERAIM, MicrobPredict and SALVE.

Log in to post comments